Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.
Nitric Oxide. 2012 May 15;26(4):285-94. doi: 10.1016/j.niox.2012.03.014. Epub 2012 Apr 5.
Vascular intimal hyperplasia (IH) limits the long term efficacy of current surgical and percutaneous therapies for atherosclerotic disease. There are extensive changes in gene expression and cell signaling in response to vascular therapies, including changes in nitric oxide (NO) signaling. NO is well recognized for its vasoregulatory properties and has been investigated as a therapeutic treatment for its vasoprotective abilities. The circulating molecules nitrite (NO(2)(-)) and nitrate (NO(3)(-)), once thought to be stable products of NO metabolism, are now recognized as important circulating reservoirs of NO and represent a complementary source of NO in contrast to the classic L-arginine-NO-synthase pathway. Here we review the background of IH, its relationship with the NO and nitrite/nitrate pathways, and current and future therapeutic opportunities for these molecules.
血管内膜增生（IH）限制了目前用于动脉粥样硬化疾病的手术和经皮治疗的长期疗效。血管治疗会引起广泛的基因表达和细胞信号变化，包括一氧化氮（NO）信号的变化。NO 因其血管调节特性而广为人知，并已被作为治疗血管保护作用的治疗方法进行了研究。循环分子亚硝酸盐（NO2(-)）和硝酸盐（NO3(-)）曾经被认为是 NO 代谢的稳定产物，现在被认为是 NO 的重要循环储存库，与经典的 L-精氨酸-NO-合酶途径相比，它们代表了 NO 的另一种补充来源。在这里，我们回顾了 IH 的背景、它与 NO 和亚硝酸盐/硝酸盐途径的关系，以及这些分子的当前和未来治疗机会。
